Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Your research
Country: Germany,Spain,United States,Australia,Canada,Israel,France,South Africa,Italy,Slovenia - Phase: complete
nct
Update Il y a 5 ans
Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical Study
The AC-055B201/MUSIC study is a Phase II study, comparing one dose of ACT-064922 (macitentan) 10 mg with placebo in patients with idiopathic pulmonary fibrosis (IPF). The main study objective is to demonstrate that macitentan positively affects the forced vital capacity (FVC) in comparison with placebo in patients with idiopathic pulmonary fibrosis (IPF). The secondary objectives are to evaluate the effect of macitentan on the time to disease worsening or death in patients with IPF, and to evaluate the benefit/risk profile of macitentan in the treatment of patients with IPF.
Country
Australia
,
Canada
,
France
,
Germany
,
Israel
,
Italy
,
Slovenia
,
South Africa
,
Spain
,
Sweden
,
Turkey
,
United States
,
organs
None
Specialty
None
Closed trial
More information
1